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Abstract
Background: The present literature review is part of the NNR5 project with the aim of reviewing and updating
the scientific basis of the 4th edition of the Nordic Nutrition Recommendations (NNR) issued in 2004.
Objective: The objective of this systematic literature review was to assess the health effects of different intakes
of iron, at different life stages (infants, children, adolescents, adults, elderly, and during pregnancy and
lactation), in order to estimate the requirement for adequate growth, development, and maintenance of
health.
Methods: The initial literature search resulted in 1,076 abstracts. Out of those, 276 papers were identified
as potentially relevant. Of those, 49 were considered relevant and were quality assessed (A, B, or C).
An additional search on iron and diabetes yielded six articles that were quality assessed. Thus, a total of 55
articles were evaluated. The grade of evidence was classified as convincing (grade 1), probable (grade 2),
suggestive (grade 3), and inconclusive (grade 4).
Results: There is suggestive evidence that prevention or treatment of iron deficiency (ID) and iron deficiency
anemia (IDA) improves cognitive, motoric, and behavioral development in young children, and that
treatment of IDA improves attention and concentration in school children and adult women. There is
insufficient evidence to show negative health effects of iron intakes in doses suggested by the NNR 4. There
is insufficient evidence to suggest that normal birth weight, healthy, exclusively breast-fed infants need
additional dietary iron before 6 months of life in the Nordic countries.
An iron concentration of 48 mg/L in infant formulas seems to be safe and effective for normal birth weight
infants. There is probable evidence that iron supplements (12 mg/kg/day) given up to 6 months of age to
infants with low birth weight (B2,500 g) prevents IDA and possibly reduce the risk of behavioral problems
later on. There is probable evidence that ID and IDA in pregnant women can be effectively prevented by iron
supplementation at a dose of 40 mg/day from week 1820 of gestation. There is probable evidence that a high
intake of heme iron, but not total dietary, non-heme or supplemental iron, is associated with increased risk of
type 2 diabetes (T2D) and gestational diabetes.
Conclusions: Overall, the evidence does not support a change of the iron intakes recommended in the NNR 4.
However, one could consider adding recommendations for infants below 6 months of age, low birth weight
infants and pregnant women.
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I
ron is essential not only for hemoglobin (Hb)
production and oxygen transport but also for many
enzymes involved in, e.g. cellular energy metabolism.
Mild iron deficiency (ID) will lead to depleted iron stores,
usually defined as a low serum ferritin (s-Ft). More severe
ID will lead to iron deficiency anemia (IDA). Globally,
IDA is the most common micronutrient deficiency with
about 600 million affected (1). ID and IDA have been
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associated with poor physical, cognitive and behavioral
performances, impaired neurodevelopment in children
as well as growth inhibition, hypertension and reduced
immune function (25).
Iron is unique among nutrients because the human
body has no mechanism for iron excretion and exces-
sive iron intakes can therefore result in iron overload
if intestinal iron absorption is not sufficiently down-
regulated. Since iron absorption is homeostatically regu-
lated, at least in adults, the risk of iron overload from
dietary iron is mainly limited to individuals with here-
ditary hemochromatosis, a relatively common disorder
in the Nordic countries, with a reported frequency of
homozygosity for the C282Y mutation ranging from
0.20 to 0.75% (68). However, high dietary iron intakes
may have adverse effects even in the absence of iron
overload, since iron is a very reactive element and a
potent pro-oxidant. High iron intakes and high serum
ferritin concentrations have been suggested to be asso-
ciated with poor growth, cancer, cardiovascular disease,
infections, and diabetes (913).
Iron requirements are very different depending on
age and gender. Individuals at highest risk of ID are
young children and fertile women. Due to the normal
iron endowment at birth, healthy, term, normal birth
weight infants are theoretically virtually independent on
external iron during the first 6 months of life. However,
after that age, infants and toddlers have very high dietary
iron requirements (about 1 mg/kg/day) due their rapid
growth. Breast milk as well as cow’s milk has a low iron
content so young children need iron-rich complementary
foods or iron supplements to achieve these intakes.
The other risk group for ID is fertile women, primarily
due to their iron losses associated with menstruation.
Furthermore, it is believed that women are adapted to
a lower iron status than men. Indeed, in contrast to
other biomarkers for nutrition, there are gender-specific
cut-offs for the definition of ID and IDA, allowing lower
iron status markers in fertile women. During pregnancy,
iron requirements are increased due to the iron needs of
the growing fetus.
ID is usually defined using one or several of the
available markers of iron status, including serum ferritin,
transferrin saturation, soluble transferrin receptors,
zinc protoporphyrin, mean cell volume, red cell distribu-
tion width, reticulocyte Hb, and hepcidin. Serum ferritin
is the most commonly used marker of iron status and
has been shown to closely parallel the size of body iron
stores in adults as measured by bone marrow staining
or repeated phlebotomy. However, it is important to note
that serum ferritin will be elevated in a state of infection,
inflammation or liver disease, limiting the usefulness of
serum ferritin for diagnosis of ID in those cases.
In the 4th edition of Nordic Nutrition Recommenda-
tions (NNR) issued in 2004 (NNR 2004), the recom-
mended daily intake (RDI) of iron was set to 8 mg/day
for children from 6 months to 5 years of age, 9 mg/day for
children 69 years, 11 mg/day for 1017-year old boys
and for 1013-year old girls, 15 mg/day for 1417 year
old girls and for women of childbearing age, including
lactating women, and 9 mg/day for adult men and post-
menopausal women. Even though the NNR 2004 stated
that the physiological need of some women for iron
cannot be satisfied during the last two thirds of preg-
nancy with foods only and that supplemental iron is
needed, the NNR 2004 did not give a specific recom-
mendation for iron intake for pregnant women. Further-
more, the NNR 2004 did not give recommendations for
iron intake for infants below 6 months of age.
The present systematic literature review is a part of the
NNR5 project with the aim of reviewing and updating
the scientific basis of the 4th edition of the NNR issued in
2004 (Nord 2004:13). A number of systematic literature
reviews will form the basis for establishment of dietary
reference values in the 5th edition of NNR.
Aims
The overall aim was to review recent scientific data on
health effects of different dietary iron intakes at different
life stages (infants, children, adolescents, adults, elderly,
and during pregnancy and lactation), in order to estimate
the requirements for adequate growth, development, and
maintenance of health.
Research questions
Two specific research questions were developed:
(1) What is the minimal dose of dietary iron intake that
will prevent poor functional or health outcomes in
different age groups within the general population
including the risk groups for ID?
(2) What is the highest dose of dietary iron intake that is
not associated with poor functional or health out-
comes in different age groups within the general
population including some risk groups for iron
overload?
Dietary iron intake was defined as intake for at least
6 months (3 months for infants) from dietary sources or
iron supplements. However, some of the included inter-
vention studies were designed with shorter exposure time.
The main functional or clinical outcomes of interest
were anemia, cognitive/behavioural function, growth and
development, and adverse effects, including the possible
risk of cancer and cardiovascular disease.
Methods
Search terms were defined during 2010, in collabora-
tion with Jannes Engqvist, librarian at the Swedish
National Food Agency. The search terms are presented
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in Appendix 1. In addition, the six papers not included
in the original search were found by searching through
reference lists of relevant papers known to the authors.
Thus, the final search resulted in 1,076 abstracts. Studies
published from January 2000 until September 2010 where
included. Abstract screening was conducted according to
the guidelines for Systematic Literature Reviews for the
5th edition of the NNR. Inclusion criteria in the abstract
screening process were the following: Nordic or English
language, study population relevant for Nordic countries
(excluding populations from low- or middle-income
countries in Africa, South America, and Asia), study in
healthy humans of relevance to the research questions,
full paper (excluding letters, news articles, and congress
reports). Of the 1,076 abstracts, 276 fulfilled these criteria
and were ordered as full-text articles. Each full text article
was screened by two of us and additional papers were
excluded according to the following criteria: effect of iron
intake not measured, unhealthy population, no health
outcome reported, general (non-systematic) review,
iron intake from both diet and supplement not assessed.
After this exclusion, 49 articles remained and were
quality assessed. The full exclusion history is provided
in Appendix 2. The selected papers were grouped
according to clinical outcomes and different age stages
into the following categories:
Anemia and iron status outcomes (specifically iron
status in fertile women, pregnant women, and infants),
physical performance, cognition and behavior, fetal and
child growth, interactions with other food components
(including tea, zinc, and copper), adverse effects (includ-
ing cancer, cardiovascular disease, gastrointestinal effects,
hypospadia, Barrett?s esophagus, rheumatoid arthritis,
and type 2 diabetes [T2D]).
To ensure the inclusion of the most recent evidence,
a complementary search was conducted at the end of
January 2012 covering the period between the first search
until the end of December 2011. This search resulted in
187 abstracts. Following the same procedure as in the
main search, 79 and 61 abstracts were excluded during
two rounds of evaluation according to the criteria of
Level 13 (Appendix 2). After this, 47 abstracts remained
and were obtained as full text papers. Quality assessment
according to Level 4 (Appendix 2) was performed on
papers regarded as particularly important by the expert
group. After a thorough systematic review of papers
relevant for each outcome, the evidence was graded as
either convincing (grade 1), probable (grade 2), suggestive
(grade 3) or no conclusion.
The term ‘diabetes’ was unintentionally lacking in the
original search. When this was discovered (June 2012),
a simple supplementary search in PubMed using the
term ‘dietary iron diabetes’ was performed. This pro-
duced 132 abstracts for the period 1 January 200031
December 2011. Following the same procedure as in the
main search, 124 abstracts were excluded. The remaining
eight abstracts were obtained as full text articles, and were
evaluated with the Quality Assessment Tool (QAT). This
resulted in the exclusion of another two articles, leaving
six studies on the association between dietary iron intake
and diabetes. Thus, a total of 55 articles (49 from the
original search, six from the diabetes search) were
evaluated using the QAT.
Results
To evaluate the quality of the selected articles (N55),
we used the QAT received from the NNR5 secretary.
The QAT included questions about study design, recruit-
ment, compliance, dietary assessment, confounders, sta-
tistics, outcomes, etc. The summary of findings from
studies graded as A or B according to QAT is presented
in Summary Tables 111. Main results of the papers
graded C are given in the text, but those studies are not
used in the final grading of evidence.
Anemia and iron status
Infants and young children
Iron supplements are usually not recommended for
healthy, breast-fed infants. However, two recent studies
have examined the effects of iron supplements (77.5 mg/
day, corresponding to 12 mg/kg/day) given to term,
normal birth weight breast-fed infants from 1 to 6
months of age. In the study by Friel et al. (study quality
B), a significant effect was observed in Hb at 6 months
but no remaining effect at 12 months (14). A weakness of
this study was low power and a high attrition rate. In the
study by Ziegler et al. (study quality B), a transient effect
on s-Ft was observed at 6 months, which no longer
remained at 9 months (15). In addition, we included
2 randomized controlled trials (RCTs) of iron supple-
ments given to breast-fed infants from 4 months of age.
In the study by Yurdako¨k et al. (study quality B), no
effect was observed on iron status at 7 months after
giving iron supplements (1 mg/kg/day or 7 mg/kg/week)
(16). In the study by Domello¨f et al. (study quality A),
a significant effect on iron status, including Hb, was
observed in Swedish infants receiving iron supplements
(1 mg/kg/day) from 4 to 9 months of age, but there was
no reduction in the already-low prevalence of IDA (17).
Taken together, these four studies give probable evidence
(grade 2) that iron supplementation of breast-fed infants
results in a transient increase in iron status (Hb or s-Ft).
However, since no reduction in IDA was observed, the
data do not support that term, normal birth weight,
healthy, breast-fed infants need additional dietary iron
before 6 months of life in populations with a low general
prevalence of IDA such as the Nordic countries.
In a study by Hernell and Lo¨nnerdal (study quality B),
term, normal birth weight infants were randomized to an
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infant formula with 2 or 4 mg Fe/L from 1 to 6 months
of age (18). No significant difference in iron status
was observed at 6 months. However, this was a very
small study with only 1012 infants in each group so it
was not powered to study effects on ID or IDA. Based on
this study, no conclusive evidence (grade 4) can be made
regarding whether an iron concentration of 2 mg Fe/L
infant formula is sufficient to prevent ID.
We included two cohort studies investigating iron
intakes and iron status in Icelandic and New Zealand
children (19, 20). Gunnarsson et al. (study quality A)
measured iron intake and iron status in 70 Icelandic 2-
year-olds and found low s-Ft concentrations (B12 mg/L)
in 27%, an ID prevalence of 9% (defined as s-FtB12 mg/
L and mean corpuscular volume (MCV) B74 fL), and
only one case of IDA (ID and HbB105 g/L). Mean (SD)
iron intake in that study was 7.57 (4.2) mg/day, which is
slightly lower than the NNR4 recommendation of 8 mg/
day. Interestingly, Gunnarsson et al. found no significant
correlation between iron intakes and iron status in this
study but found that a high intake of cow’s milk (]450
mL/day) was significantly associated with ID (19). Heath
et al. (study quality B) investigated iron intakes and iron
status in a cohort of 74 New Zealand children followed
from 9 to 24 months of age (55 remained at 24 months)
(20). At 9 months of age, median iron intake was 7.0 mg/
day, which is slightly lower than the NNR4 recommenda-
tion of 8 mg/day. However, at 1224 months, median iron
intakes were 4.34.9 mg/day. Still, the prevalence of IDA
in this cohort was relatively low: 7% at 918 months of
age and no case of IDA was found at 24 months. In this
study, IDA was defined as HbB110 g/L and MCVB77
fL, i.e. higher cut-offs than the Icelandic study and,
unusually, s-Ft was not included in the definition of IDA.
The correlation between iron intakes and iron status was
not reported in this study.
In conclusion, both of these studies report a lower iron
intake than recommended in 924 month-old children
but the prevalence of IDA was low at 24 months of age.
The finding of a significant association between cow’s
milk intake 500 ml/day and ID in the Icelandic study
supports previous Nordic data suggesting that a high
cow’s milk intake (in that study 300 mL/day) is
associated with an increased risk of ID in toddlers.
Fertile women
The original search returned no articles examining the
dietary intake of iron and iron status in free-living, iron-
replete women of childbearing age.
One small study (study quality B) examined iron
status markers in 25 iron deficient women consuming
an oily fish or a red meat diet, in a randomized crossover
dietary intervention study of two 8-week periods (21). At
inclusion, the women (aged 1830 years) were menstruat-
ing, non-smoking, non-anemic (Hb11 g/dL), had low
iron stores (FtB30 mg/L), had not used iron supplements
for the last 12 months, had no chronic gastric or iron-
metabolism related disease, had no fish allergy, or were
not vegetarian. The average dietary iron intake was 11.54
mg/day during the oily fish diet, and 13.93 mg/day during
the red meat diet, both diets providing a lower daily iron
intake than the NNR4 recommendation for menstruating
women (15 mg/day). The study found a non-significant
increase in s-Ft and a non-significant decrease in serum
transferrin receptors (sTfR) during the red meat diet,
and opposite, non-significant changes during the oily fish
diet. The authors concluded that an oily fish diet does
not decrease iron status in iron deficient women during
8 weeks compared to a red meat diet.
The complementary search yielded two studies that
addressed iron status of iron deficient fertile women.
One was a Cochrane review, whereas the other was an
intervention study examining the effect of microencapsu-
lated iron-pyrophosphate-fortified fruit juice (22, 23).
The Cochrane review examined the effect of inter-
mittent iron supplementation versus no intervention or
placebo. However, of the 21 studies included, only one,
small study (N24) was on a population relevant to
NNR5 (24). The authors conclude, in line with the
general conclusion of the Cochrane review, that daily
supplementation with 50 mg Fe can provide a better
correction of ID than a twice weekly supplementation of
50 mg Fe for 3 months in young women with low s-Ft
levels.
The intervention study lasted for 16 weeks and
supplied 18 mg Fe/day as microencapsulated iron-
pyrophosphate in 500 mL fruit juice (Fe group N58),
or fruit juice only (placebo group, N64) to women aged
1835 years, non-smoker, non-pregnant, non-breastfeed-
ing, with low iron stores, defined as s-FtB40 ng/mL and
Hb 110 g/L (23). At baseline, the average daily iron
intake was 15.1 mg in the placebo group and 13.7 mg in
the Fe group. During the 16 weeks, the Fe group had an
average iron intake of 30.4 mg/day, whereas the intake of
the placebo group actually declined to 12.9 mg Fe/day.
The mean s-Ft value of the placebo group remained
constant over the intervention period (Start: 26.9 ng/mL,
End: 22.8 ng/mL), whereas the mean s-Ft in the Fe group
increased significantly from 25.4 to 40.7 ng/mL. The
authors conclude that their results suggest that iron-
fortified fruit juice could be used as dietary treatment
to effectively correct anemia. The study shows that daily
intake of an iron-enriched fruit juice results in increased
s-Ft concentrations in healthy, non-anemic menstruat-
ing women. However, the study does not show that the
additional iron reduces the prevalence of ID or IDA.
Thus, the available literature present no new information
and allow no new conclusions to be drawn regarding
any health outcomes following high or low dietary iron
intake by healthy fertile women.
Magnus Domello¨f et al.
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Pregnant women
We found a total of seven studies that examined various
aspects of the association of iron supplement intake and
anemia in pregnancy. Two studies examined the effect
of supplementing with a low iron dose from week 1820
of gestation to delivery or 8 weeks postpartum (25, 26).
Two studies investigated the benefit of adjusting iron
supplementation based on s-Ft values in early pregnancy
(27, 28). One study examined short term effect of iron
supplementation from week 20 to 28 of gestation (29),
one study looked at healthy, iron sufficient adolescent
and adult women receiving iron from week 1016 of
gestation until term (30), and another study looked at the
effect of iron supplementation from day 4 after delivery
to the end of the 3rd month postpartum (31).
Milman et al. (study quality B) followed 427 women
from 18 weeks of gestation to 8 weeks postpartum (25).
The participants were randomly assigned to one of four
groups receiving 20, 40, 60, or 80 mg Fe/day as ferrous
sulphate. Compliance was 90%. The frequency of ID
(defined as FtB13 mg/L) or IDA (defined as ID with
HbB106 g/L at 18 weeks, HbB105 g/L at 32 weeks,
HbB115 g/L at 39 weeks, HbB123 g/L at 8 weeks
postpartum) at inclusion did not differ between the
groups. However, at 32 weeks of gestation the frequency
of ID in the 20 mg Fe group (50%) was significantly
higher than the frequency in the 40 mg (26%), the 60 mg
(17%) and the 80 mg group (13%). Similar, significant
differences were found at 39 weeks of gestation (29, 11,
10, and 9%). At 8 weeks postpartum, no statistically
significant differences in ID frequencies were found
(6.7, 2.9, 2.1 and 0%). The prevalence of IDA at 32
weeks was not different between the four groups. At 39
weeks, the prevalence in the 20 mg Fe group (10%) was
higher than the other three groups (4.5, 0, and 1.5%). At
8 weeks postpartum, the prevalence of IDA was low and
equal in the four groups (0, 0, 2.1 and 0%, respectively).
The authors conclude that in Danish women supple-
mentation with 40 mg Fe/day from 18 weeks of gestation
prevents ID in 90% and IDA in at least 95% of the
women during pregnancy.
Makrides et al. (study quality A) performed a similar
study on 386 Australian women (26). From week 20 of
gestation until delivery, participants were randomly as-
signed to receive either 20 mg Fe/day (as ferrous sulphate),
or placebo. Compliance was 8586%. Iron status was
examined at delivery and at 6 months postpartum. At
delivery, the frequency of IDA (defined as FtB12 mg/L
and HbB110 g/L from week 20 until delivery, or defined
as FtB15 mg/L and HbB120 g/L at 6 months postpar-
tum) in the iron group was 3% compared to 11% in the
placebo group Relative Risk (RR) was 0.28 (95% CI: 0.12
0.68; PB0.005). At 6 months postpartum there was
no difference in IDA frequency between the two groups.
The frequency of ID at delivery was 35% in the iron group
and 58% in the placebo group (RR0.60; 95% CI:
0.480.76; PB0.001), and at 6 months postpartum
the frequencies were 16% and 29% (RR0.57; 95% CI:
0.380.84; PB0.005) in the two groups.
The authors conclude that supplementation with 20 mg
Fe/day from week 20 of gestation is an effective strategy
for preventing IDA and ID.
Milman et al. (25) did not actually measure iron intake
from foods, but give a reference to the average iron intake
of Danish women of 8.59.1 mg Fe/day (32). Makrides
et al. using a food frequency questionnaire (FFQ), found
an average intake of iron from foods of approximately
14 mg/day (26). Thus, an iron supplement dose of 20
mg/day as used by Makrides et al. would exceed the
US recommendation (33) for dietary iron of 27 mg/day
1.25fold, whereas the 40 mg Fe/day dose suggested by
Milman et al. is 1.8-fold higher.
Taken together, these two studies strongly suggest that
supplementation with 2040 mg Fe/day (corresponding
to a total iron intake of 3449 mg/day) from week 1820
of gestation would be effective in preventing ID and IDA
during pregnancy This conclusion is also supported
by the two studies of Sandstad et al. (study quality B),
and Milman et al. (study quality B) in which iron
supplementation was adjusted according to s-Ft concen-
trations in early pregnancy (27, 32). Sandstad et al.
compared the effect of giving advice only (Group I) with
giving advice in combination with iron supplementa-
tion (Group II), on iron status 6 weeks postpartum (27).
They found no differences between the two groups, i.e.
giving advice only works just as well as actively giving
the women iron supplements. Through the design of the
study, Group II was split into Group IIa (receiving 60 mg
Fe/day as ferrous sulphate) and IIb (receiving 27.6 mg Fe/
day as 24 mg Fe in the form of ferrous fumarate and
3.6 mg Fe in the form of heme iron). Group IIa had
significantly higher s-Ft at 6 weeks postpartum compared
to Group IIb (PB0.05), and the increase in s-Ft from
early pregnancy until 6 weeks postpartum was signifi-
cantly higher in IIa compared to IIb (PB0.04). The
prevalence of empty iron stores, defined as s-FtB12 mg/
L, at 6 weeks postpartum was 4.8%. The authors con-
clude that iron supplementation based on iron status in
early pregnancy resulted in adequate iron stores at 6
weeks postpartum. However, the main indicator for iron
status at 6 weeks postpartum was peripartum blood loss.
Milman et al. allocated 301 healthy, pregnant Danish
women into four groups receiving 20, 40, 60 or 80 mg Fe/
day, respectively, from week 18 of gestation until 8 weeks
postpartum (28). The participants in the four iron groups
were stratified according to their s-Ft concentrations.
At inclusion 50.7% had s-Ft 5 30 mg/L, 37.7% had s-Ft
3070 mg/L, and 11.6% had s-Ft70 mg/L. At delivery
women with s-Ft 5 30 mg/L in early pregnancy had ID
frequencies of approximately 27, 17, 7 and 7% in the 20,
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40, 60 and 80 mg Fe/day groups, respectively (PB0.001).
Women with s-Ft between 30 and 70 mg/L in early
pregnancy had ID frequencies of approximately 23, 0,
11 and 4% in the four iron groups (PB0.001). Women
with s-Ft70 mg/L at inclusion had no ID. The fre-
quency of IDA at delivery was low, and none of
the women with s-Ft30 mg/L had IDA. The authors
suggest that to prevent ID, supplementation with 80100
mg Fe/day to women with s-Ft 5 30 mg/L in early preg-
nancy, and 40 mg Fe/day for women with s-Ft between
30 and 70 mg/L, is sufficient. There is no need for iron
supplement in women with s-Ft70 mg/L.
Taken together, these two studies suggest that adjusting
iron supplementation on an individual basis according to
s-Ft values in early pregnancy may be of some benefit.
Those with s-Ft below 2030 mg/L would benefit from
receiving an iron dose of 4060 mg Fe/day, and iron-
replete women (s-Ft6070 mg/L) would not have to take
iron supplements at all.
The data in the four studies above present probable
evidence (grade 2) showing that if we want to prevent ID
in more than 90% and IDA in more than 95% of women
at delivery and at 68 weeks postpartum, supplementa-
tion with 40 mg Fe/day from week 1820 of gestation
will achieve this. The same supplementation regime
would prevent ID in 83% of women having s-FtB30
mg/L in early pregnancy, and in 100% of women having
s-Ft between 30 and 70 mg/L in early pregnancy. At 68
weeks postpartum ID and IDA would be prevented in
100% of women. For women with Ft70 mg/L in early
pregnancy, iron supplementation would normally be
unnecessary.
As part of a study on birth weight, Cogswell et al. (study
quality B) also measured iron status in 275 pregnant,
iron sufficient women (Hb110 g/L and s-Ft20 mg/L),
randomly assigned to receive iron supplements (30 mg Fe/
day) or placebo from week 20 to week 28 of gestation (29).
They found no differences between iron and placebo with
regard to the proportion of women with anemia, low iron
stores, or IDA. After adjustment for pre-pregnant weight
and log initial s-Ft the prevalence of absent iron stores
and IDA was significantly lower in the iron-supplemented
group compared to the placebo group.
Meier et al. (study quality C) examined 111 healthy,
iron sufficient (median s-Ft30 mg/L), pregnant adoles-
cent (1518 years) or adult (19 years) women, randomly
assigned to receive placebo or iron supplementation (60
mg Fe/day) from week 1016 of gestation until delivery
(30). Compliance as measured by pill count, was 8498%.
Overall, 47% of the placebo group and 16% of the iron
group exhibited IDA (PB0.001). Among the adolescents
59% of the placebo group and 20% of the iron group
exhibited IDA (P0.021) at delivery. Median Hb and
s-Ft values in adolescents were significantly higher at term
in the iron group 1. In adults s-Ft (but not Hb) was
significantly higher at second trimester as well as at term
in the iron group compared to the placebo group.
The study by Mara et al. (study quality C) examined
the effect of supplementing with 80 mg Fe/day (as the
commercial product Tardyferon) either alone (N20) or
in combination with 0.35 mg folic acid/day (Tardyferon
Fol) (N20) starting at 4 days after delivery and
continuing until the end of the 3rd month postpartum
(31). A control group (N20) received no supplement.
At delivery a total of 61.7% of the women were anemic,
defined as HbB11 g/dL. At 1 month postpartum, 15%
of women receiving iron alone were anemic compared to
50% in the control group (P0.041, Fisher’s exact test,
authors’ calculation). At 2 months postpartum, 10% of
the Fe group was anemic compared to 35% of the control
group (P0.127, Fisher’s exact test, authors’ calcula-
tion). At 3 months postpartum, only one woman in the
control group remained anemic. The authors recommend
flat administration of 80 mg Fe/day to all women for
at least 3 months after delivery. In our opinion, this
small study shows that 80 mg Fe/day, at best, reduces the
frequency of anemia during the 1st month postpartum.
After 23 months, there is no difference between the
group receiving iron and the control group. Thus, the
study data does not support the recommendations given
by the authors.
In addition, a systematic review and meta-analysis
was published in 2009 covering the effects of preventive
oral iron supplementation during pregnancy (34). The
review considered 49 publications published between
1958 and 2008, and two of the studies included in the
current review (26, 33). were among the 49 articles
covered by the review. Unfortunately, most of the studies
in the meta-analysis are published before year 2000,
or are performed in populations not relevant to NNR.
Furthermore, information on iron dosage and/or food
iron intake is missing. In general, however, the seven
studies included in our analysis are in line with the results
reported in the meta-analysis.
Effects on offspring of iron supplementation of pregnant
women
Iron supplementation of pregnant women has been
suggested to improve iron status in the newborn. How-
ever, iron transport to the fetus is an active process and the
fetus may be protected from ID even when the mother has
mild or moderate IDA. This review includes one RCT by
Zhou et al. (study quality A), evaluating the effect of 20
mg Fe/day versus placebo given to pregnant Australian
mothers from mid-gestation until delivery (35). No sig-
nificant effect was observed with regard to offspring iron
status at 6 months or 4 years of age. This is supported by
the systematic review by Pena-Rosas (34) (study quality
A) which concludes that there is a lack of convincing
evidence that iron supplementation during pregnancy
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improves infant iron status, even though this was sug-
gested by a single study performed in an Nigerian
population with a very high prevalence of IDA (36).
In summary, there is no conclusive evidence (grade 4)
that iron supplementation of pregnant women in a
Scandinavian setting would improve infant iron status.
See Summary Table 1.
Physical performance
Two studies have examined the effect of iron on physi-
cal performance in healthy individuals. Unfortunately,
none of the studies give any quantitative data (e.g. RR
or odds ratio [OR]) on the impact of iron on physical
performance.
McClung et al. (study quality B) measured the effect of
iron supplementation on 2-mile run time (main physical
performance outcome) in female soldiers during basic
combat training (BCT) (37). The study was an 8-week
randomized, double-blind, placebo-controlled trial (evi-
dence quality B), where the intervention group (N86)
received 15 mg Fe/day as Fe(II)-sulphate. Iron intake
from foods was estimated, but not measured, to a
minimum of 3 mg/day. This was the only iron intake in
the placebo group (N85). Approximately 16 and 21%
of the participants presented with ID or IDA, respec-
tively, at baseline. The number of individuals with ID or
IDA was equally distributed between the intervention
group and the placebo group. The main biochemical
finding was that iron supplementation attenuated the
decline in iron status observed during BCT. This effect
was relatively larger in individuals with ID or IDA at
baseline. The 2-mile run time post-BCT did not differ
between the iron group and the placebo group in iron-
replete or ID participants. However, in individuals with
IDA at baseline the placebo group had a significantly
longer run time compared to all other groups. Further-
more, the placebo group run time of the IDA participants
was on average 110 sec longer than the IDA iron group.
Thus, physical performance of IDA individuals after
receiving iron supplements during 8 weeks BCT is similar
to that of iron-replete individuals. Iron supplementation
to iron-replete or ID individuals has apparently no effect
on physical performance, at least not when assessed by
2-mile run time.
The second study (study quality C) was performed on
adolescent swimmers (21 male, 21 female) aged 1217
years and without ID or IDA, during a 6-month training
season (38). The participants were equally allocated to
three groups of similar age, performance level, and iron
status. Group A followed their ordinary diet, but received
47 mg Fe/day as supplement (average total iron intake of
58 mg/day). Group B followed a diet plan rich in iron
(average total iron intake of 26 mg/day), whereas Group
C followed their normal diet (average total iron intake
of 12 mg/day). The groups were followed during the
different phases of the training season, and physical
performance was assessed by various swimming tests.
Although significant fluctuations in iron status during
the training season could be observed, no significant
differences in iron status or performance between the
three groups could be found. The authors conclude that
‘iron status and performance of healthy adolescent
swimmers were affected by training irrespective of iron
intake ranging from one to over five times the RDA over
a period of 6 months’.
Taken together, these two studies yield inconclusive
evidence (grade 4) that iron supplementation increases
physical performance in iron-replete individuals, but
limited  suggestive evidence that iron supplementa-
tion enhances physical performance in individuals with
IDA.
Cognitive and behavioral function
Effects on the offspring of iron given to the pregnant mother
This review includes two publications (both study quality
A) from the same Australian RCT assessing the effects
of iron supplementation during pregnancy on offspring
cognitive/behavioral function (39, 40). These studies
show that iron supplements (20 mg/day) during the
last half of gestation did not have any effect on cognitive
function at 4 years or on behavioral scores at 68 years
in the offspring. The studies provide no conclusive
evidence (grade 4) that iron supplementation during
pregnancy improves cognitive or behavioral outcomes in
the offspring.
Effects of iron given to infants and children
Only one included intervention trial was performed in a
low-risk population comparable to the Nordic popula-
tion (14). That trial, performed by Friel et al. (study
quality B), investigated the effects of iron supplements
(7.5 mg daily; corresponding to 12 mg/kg/day) given
from 16 months of age to healthy, term, normal birth
weight, breast-fed Canadian infants and showed signifi-
cantly better psychomotor development in iron supple-
mented infants at 1218 months of age (PDI 100 vs. 93)
(14) However, this was a small study with high attrition
and only 26 iron supplemented and 20 control infants
analysed, leaving the possibility of a type I error.
A recent meta-analysis (study quality A), based on
only three RCTs showed that iron supplements to non-
anemic infants has a significant positive effect on
psychomotor scores but no effect on mental develop-
ment index at 12 months of age (41). One of these RCTs
was the Friel trial described above and the other two
were performed in high-risk populations (Indonesia (42)
and very low-income Canadian families (43)), making it
difficult to translate these results directly to the Nordic
population.
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Fetal and child growth
Fetal growth and pregnancy duration
Iron given to pregnant women has previously been
suggested to improve fetal growth and result in higher
birth weights. We included one cohort study (study quality
B) and one meta-analysis (study quality A) of the effects
on fetal growth (34, 44). The cohort study showed that
iron intake (from diet and supplements) in pregnant
adolescents was not significantly associated with growth
restriction (small for gestational age at birth) or preterm
birth (44). Similarly, the meta-analysis by Pena-Rosas,
including 10 trials and 6,000 subjects, showed that
iron supplements during pregnancy had no significant
effect on birth weight or the proportion of infants with
low birth weight (B2,500 g) (34). Based primarily on
the meta-analysis, we judge that there is no conclusive
evidence (grade 4) that iron supplements during preg-
nancy improve fetal growth, or reduce the proportion of
children born prematurely, small for gestational age or
with low birth weight.
Child growth
Additional iron given to iron-replete infants has been
suggested to impair growth. We included one RCT (study
quality A) and one meta-analysis (study quality A)
regarding the effects of iron on child growth. The RCT
showed that iron supplements at a dose of 1 mg/kg/day
from 49 or 69 months of age significantly impaired
longitudinal growth (9). This effect was mainly seen in
those Swedish infants who were iron-replete and had a
high initial Hb concentration, suggesting that iron
supplements may impair growth in iron-replete infants
who do not belong to a risk group for IDA. On the other
hand, a meta-analysis by Ramakrishnan including 27
trials (most in low-income countries) showed no signifi-
cant effect of iron supplements on growth in children B5
years of age (45). However, children were not stratified by
initial iron status in the meta-analysis. In summary, there
is no conclusive evidence (grade 4) that iron supplements
impair growth in iron-replete children.
Hypertension and cardiovascular disease
There were four papers on iron intake and hypertension,
and one on iron intake and mortality from cardiovas-
cular disease; all papers were evaluated to be of quality
B. See Summary Table 7. Additionally, the recent sys-
tematic review of the UK Department of Health was
considered (46).
Hypertension
Two of the studies concerned maternal intake of iron
during pregnancy and blood pressure of the offspring
aged 3 and 7 years (47, 48). A study by Belfort et al. (47)
showed that by each 10 mg increase in iron intake in the
first trimester, systolic blood pressure of 3-year-olds
increased by 0.4 mm Hg (95% CI: 0.10.7) (47). Brion
et al. (48) found no effects of maternal total iron intake
on child’s blood pressure when all confounders were
included. Those women who had received iron supple-
ment at any trimester in pregnancy had a significantly
lower systolic blood pressure, 0.63 mm Hg (95% CI: 
1.09(0.17)) (48). Belfort et al. (47) found no effects
from mothers‘ iron status in pregnancy on the children‘s
blood pressure, but Brion et al. (48) saw a positive asso-
ciation between anemia in early pregnancy and child‘s
blood pressure (see Summary Table 7). Two other studies
on blood pressure and iron intake in adults were ex-
plored, one prospective observational study and one cross
sectional study (49, 50). Both of these studies found
an inverse association between iron intake and blood
pressure (see Summary Table 7). Low non-heme iron
intake associated negatively with systolic blood pressure
and with hypertension in all models tested in the 5.4 years
prospective study. The third tertile of intake of non-heme
iron had OR0.63 (95% CI: 0.410.96) compared to the
first tertile, i.e. average intake of 13.7 mg/day non-heme
iron had 37% lower risk for hypertension than those with
7.7 mg/day on average (49). This study was supported
by a number of public and private enterprises, but the
authors all declared no conflict of interest. Tzoulaki et al.
(50) conducted a multinational cross sectional study and
also found a negative association between both dietary
total and non-heme iron intake and systolic blood
pressure (50). Both studies found no significant associa-
tion between heme iron and blood pressure, but a positive
association between the intake of red meat and blood
pressure level (49, 50), but which became insignificant
after adjustment for dietary pattern score (49). The
evidence is inconclusive (grade 4) regarding any associa-
tion between iron intake during pregnancy and blood
pressure or hypertension in the offspring.
Cardiovascular disease
Lee et al. analyzed results from the Iowa women’s health
study cohort (study quality B) for associations between
cardiovascular disease mortality and dietary iron, zinc,
and alcohol (51). In the total sample, neither heme nor
non-heme iron was associated with the risk or cardiovas-
cular disease mortality. The authors hypothesized that
alcohol is a trigger of disturbing iron homeostasis
creating a redox active non-transferrin form of iron.
Heme iron intake associated positively with cardiovascu-
lar disease mortality when alcohol intake was above 10 g/
day and stronger when it was higher, e.g. above 30 g/day
(see Summary Table 7). Highest intake quintile vs. lowest
of heme iron gave RR 2.47 (CI: 1.15.55) when alcohol
intake was above 10 g/day. When alcohol consumption
was 30 g/day, significantly higher RR was found for
third, fourth, and fifth quintile of heme iron intake
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compared to the lowest quintile of intake, i.e. RR ranged
from 2.62 (CI: 1.036.67) to 4.11 (CI: 1.1414.87).
The UK Department of Health covered iron and
cardiovascular disease in their report on iron and health
from 2010 (46). The report discusses the hypothesis
of blood loss or decreased body iron stores as protective
against cardiovascular disease. The report suggests how
iron may play a role in the development of atherosclerosis
by promoting oxidation of LDL cholesterol through
catalyzing the formation of free radicals or promoting
free radical mediated myocardial damage following an
ischemic event. The UK report includes five prospective
studies on dietary iron intake and cardiovascular disease,
which showed a median RR 1.48 of highest vs. lowest
heme iron intake, but the report also points out other
explanations for this observed association. They found no
effect of total iron intake or of body iron as s-Ft levels on
cardiovascular disease. Taken together there is no con-
clusive evidence (grade 4) about an association between
iron intake and cardiovascular disease risk even though
there is limited but suggestive evidence (grade 3) for
increased risk of cardiovascular disease following high
heme iron intake among women using more than 30 g
of alcohol per day.
Diabetes mellitus
Our search retrieved seven studies (one in the original
search, six in the diabetes search) examining the associa-
tion between iron intake and the risk of diabetes. Five
of these were of study quality B or A, and are listed in
Summary Table 8, whereas two of the studies were of
quality C and are briefly summarised here. In addition,
the complementary search yielded one article.
Type 2 diabetes
Lee et al. presented a large prospective study on the
Iowa women’s health study cohort (study quality B) (13).
They found RR1.28 (95% CI: 1.041.58) for develop-
ing T2D when comparing the 5th quintile of heme iron
intake with the 1st quintile during 11 years follow-up.
This positive association between heme iron intake and
T2D was strongest among those women who consumed
15 g/day of alcohol, even though alcohol intake itself
reduced the risk of T2D.
Rajpathak et al. (study quality A) conducted a study
within the Nurses’ Health Study cohort and followed
85,000 women for 20 years. During this time period they
documented 4,599 incident cases of T2D. Heme iron
intake was positively associated with risk; RR1.28
(95% CI: 1.141.45) for developing T2D when comparing
the 5th quintile of heme iron intake with the 1st quintile
(52). No association between total, dietary, supplemental,
or non-heme iron and risk of T2D was found. The
authors also state that no effect of alcohol consumption
could be found.
Jiang et al. (study quality B) followed 38,394 men
for 12 years, participating in the Health Professionals’
Follow-up Study (53). They found that intakes of total
heme iron (RR1.28; 95% CI: 1.021.61) and heme
iron from red meat (RR1.63; 95% CI: 1.262.10) were
associated with an increased risk of T2D. Total iron
intake or heme-iron intake, from sources other than red
meat, were not associated with risk of T2D.
Thus, the three studies above all indicate heme iron as a
risk factor for developing T2D.
This finding is indirectly supported by another, case-
control study, by Jiang et al. where they measured s-Ft
and s-Ft/Hb ratio, as markers for iron stores, in 698 cases
with T2D and 716 controls. They found RR3.20 (95%
CI: 2.224.62) for developing T2D when comparing
the 5th quintile of s-Ft with the 1st quintile. Inversely,
when comparing the 1st quintile of s-Ft/Hb ratio with the
5th quintile, they found RR2.59 (95% CI: 1.823.68).
Cases had significantly higher intake of heme iron than
controls (54).
Finally, Forouhi et al. (study quality C) investigating
360 clinically incident T2D cases with 758 controls,
nested within the EPIC (European Prospective Investi-
gation of Cancer)-Norfolk Study, found that baseline
s-Ft values were higher among cases than controls (55).
The risk of T2D was significantly elevated in those with
clinically increased s-Ft (300 ng/mL for men, 150
ng/mL for women) compared with the lowest quartile
(OR7.4; 95% CI: 3.515.4). Among the participants
with clinically raised s-Ft total iron intake was not
increased compared with the lowest s-Ft quartile, but
red meat intake and alcohol consumption was signifi-
cantly increased.
Gestational diabetes
Qiu et al. examined 3,158 pregnant women in a prospec-
tive cohort study (study quality B). Approximately 5%
(n158) of the women developed gestational diabetes
mellitus (GDM) (56) In line with the findings above they
found that women reporting the highest heme iron intake
(] 1.52 mg/day) had an increased risk (RR3.31; 95%
CI: 1.0210.72) for developing GDM compared to those
with the lowest heme iron intake (B0.48 mg/day). Non-
heme iron intake was inversely, but not statistically
significant, associated with GDM risk. From the com-
plementary search we retrieved a large study on the
association of pre-pregnancy dietary iron intake and
GDM. Bowers et al. conducted a prospective study
among 13,475 pregnant women between 1991 and 2001
in the Nurses’ Health Study II (57). Dietary information
was obtained every 4 years through a semiquantitative
FFQ. A total of 867 incident cases of GDM were
reported during the 10 years. Dietary heme iron intake
was significantly associated with GDM. Comparing
the 5th quintile of heme iron intake with the 1st quintile,
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the relative risk of developing GDM was 1.58 (95%
CI: 1.212.08). No significant associations were observed
between total dietary, non-heme, or supplemental iron
intake and GDM.
Type 1 diabetes in children
In a case-control study (study quality C) Ashraf et al.
investigated the possible association between iron intake
in infants aged 14 months and development of type 1
diabetes (T1D) before the age of 6 years (58). They found
that median total iron intake (formula, supplement
and breast milk) during the first 4 months of life
was 1,159 mg in 128 cases and 466 mg in 67 controls
(PB0.0001). Diabetes cases had significantly shorter
breastfeeding duration (4 vs. 12 weeks, P0.001), so
the higher iron intake was probably due to intake of iron-
fortified infant formula, even though formula intake was
not reported in the paper. For each standard deviation
increase in iron intake, the OR for T1D was 2.01 (95%
CI: 1.1833.41) among all participants.
Cancer
Several studies report on the possible association between
iron intake and various cancer forms.
Colon cancer
In two studies (both study quality B), in women, the risk
of proximal or distal colon cancer (59), or colorectal
adenoma (60), was assessed. The study of Lee et al. was
part of the Iowa women’s health study and followed
a cohort of 34,708 postmenopausal women for 15 years
(59). They found no association between dietary heme
iron (median intake 1.2 mg/day) or non-heme iron
(median intake 11.2 mg/day) and colon cancer. However,
the RR for incident distal colon cancer, but not for
proximal colon cancer, increased with increasing intake of
iron supplements from 0 to 50 mg/day or more, although
not statistically significant (Ptrend0.08). In the group
with highest iron supplement intake (50 mg/day), the
RR was 1.79 (95% CI: 0.943.43). On the other hand,
when stratified by intake of fermentable substrates (e.g.
insoluble or soluble fibers, or resistant starch), those
having an intake of fermentable substrates above median
(25.9 g/day), also had a significantly increased RR of 3.78
(95% CI 1.787.68, PtrendB0.01). The authors commen-
ted however, that since only nine cases were included in
the group having a daily intake of iron supplements of 
50 mg, the finding of an increased RR could have arisen
by chance.
Chan and co-workers went the other way around and
compared 527 cases of colorectal adenoma found in
the Nurses’ Health Study, with 527 matched controls
without colorectal adenoma (60). They examined a
number of biochemical iron status parameters and looked
for possible associations between iron status and color-
ectal adenoma. No statistically significant relationship
between iron status parameters and the risk of colorectal
adenoma could be found.
Taken together these studies do not give any solid
evidence supporting the hypothesis that iron is a risk
factor for developing cancer of the colon.
The complementary search yielded one additional
study on the association between iron and colorectal
cancer. Bastide et al. performed a meta-analysis on the
relationship between heme iron from meat and the risk of
colorectal cancer (61). The analysis contained 5 articles
representing 566,607 individuals and 4,734 cases of colon
cancer. One of the articles was identical to one of the
articles above (59). The relative risk of colon cancer was
1.18 (95% CI: 1.061.32) for individuals in the highest
category of heme iron intake compared with those in the
lowest category.
On the whole, the three studies (5052) deliver incon-
clusive evidence (grade 4) regarding the association
between iron intake and colorectal cancer (59, 61).
Lung cancer
Two studies (both study quality B) have examined the
possible association between iron and lung cancer. The
study of Lee and Jacobs was part of the Iowa Women’s
Health Study (62). In a cohort of 34,708 postmenopausal
women followed for 16 years, 700 lung cancer cases were
identified. The authors report no association between
total iron intake (dietary iron plus supplements) and lung
cancer. On the other hand, dietary heme iron intake was
positively associated with lung cancer when subjects were
stratified by vitamin C supplements intake. Those with
the highest heme iron intake (]2.44 mg/day) and the
highest vitamin C supplement intake (700 mg/day) had
RR8.97 (95% CI: 1.2962.51) for lung cancer com-
pared to those with lowest heme iron intake (50.77 mg/
day). Among current or ex-smokers, the association was
even stronger (RR20.38; 95% CI: 22.50185.8) and
reached statistical significance even in the group having
vitamin C supplement intake of 100 mg/day (RR
3.52; 95% CI: 1.248.97). The authors suggest that high
dietary heme iron intake in combination with high intake
of vitamin C supplements may increase the risk of lung
cancer in postmenopausal women.
In a case-control (study quality B) study, Zhou and
co-workers identified 923 cases of lung cancer at
Massachusetts General Hospital over an 8-year period
(63). Controls were recruited among healthy friends
and non-blood-related family members of patients.
Adjusted OR for total iron intake (diet plus supple-
ments) was 2.06 (95% CI: 1.313.24; Ptrend0.003),
whereas OR for total dietary iron intake was 1.45 (95%
CI: 1.032.06) when comparing the highest quintile
of iron intake with the lowest. In a multivariate model
also including dietary zinc and calcium OR increased to
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1.95 (95% CI: 1.332.86). Furthermore, when compared
with subjects in the lowest tertile of iron intake (B11.70
mg/day) and the highest tertile of zinc intake (11.69
mg/day), subjects who had the highest intake of iron
(14.32 mg/day) and lowest intake of zinc (B9.70 mg/
day) had a higher risk of lung cancer (OR2.01; 95%
CI: 0.964.2; Ptrend B0.0001). However, in contrast to
Lee and Jacobs, this study finds that the increased risk of
lung cancer conferred by dietary iron was the result
of non-heme iron intake. Heme iron was associated
with a decrease in the risk of lung cancer. The adjusted
OR for non-heme iron was 1.49 (95% CI: 1.042.14;
Ptrend0.007) whereas the OR for heme iron was 0.39
(95% CI: 0.280.56; PtrendB0.0001).
The complementary search yielded one additional
article on iron intake and lung cancer (64). Tasevska
et al. examined (among other factors) the effect of heme
iron on lung cancer risk among 99,579 participants of the
Prostate, Lung, Colorectal and Ovarian Cancer Screening
Trial. After up to 8 years of follow-up 782 incident lung
cancers (454 male, 328 female) were identified. Heme iron
intake had no effect on the risk of lung cancer.
The studies by Lee et al. and Zhou et al. both indicate
that iron may be a risk factor for lung cancer (62, 63).
However, they reach opposite conclusions on whether
heme or non-heme iron is the form of iron conferring the
risk. Tasevska et al. found no effect of heme iron (64).
All in all, these three studies deliver inconclusive
evidence (grade 4) with regard to the effect of iron intake
on lung cancer.
Breast cancer
A large study on the association between iron intake and
breast cancer was performed by Ferrucci and co-workers
(study quality B) as part of the Prostate, Lung, Colorectal
and Ovarian Cancer Screening Trial (65). The analytical
cohort consisted of 52,158 US postmenopausal women.
Incident, histologically confirmed, invasive breast cancer
cases (N1,205) were identified based on pathology
reports and medical records. There was no statistically
significant positive association for total iron (diet plus
supplements), heme iron, iron from meat, or iron from
supplements. However, total dietary iron was positively
associated with breast cancer in a dose-response manner.
Comparing the fifth to the first quintile of dietary iron
intake, the energy adjusted HR for breast cancer was 1.25
(95% CI: 1.021.52; Ptrend0.03).
From the complementary search one study addressing
the association between iron intake and the risk of breast
cancer was found (66). The study used data from the
National Institute of Health  AARP Diet and Health
study to assess intakes of dietary iron, iron from meat,
iron from red meat, and heme iron in relation to breast
cancer risk in 116,674 postmenopausal women. During
6.5 years of follow-up, 3,396 cases of invasive breast
cancer were identified. Hazard ratios for the highest
compared with the lowest quintiles of iron intakes were
all close to unity, and there were no increasing trends
with increasing iron intakes.
Taken together these two large studies provide no
conclusive evidence (grade 4) for an association between
iron intake and postmenopausal breast cancer.
Esophageal cancer
One paper on iron intake and Barrett’s Esophagus was
evaluated, quality grade B. The study by Corley et al.
was a case-control study within the Kaiser Permanente
Northern California population (67). The background for
the study lies in the hypothesis that high iron stores are
a risk factor for esophageal adenocarcinoma. Little
human data exists but Corley et al. (67) refer to studies
on animals that indicate the association. This study
evaluated whether iron intake as well as iron stores
were associated with Barrett‘s Esophagus, a metaplastic
change that is a strong risk factor for adenocarcinoma.
Between 900 and 1,000 individuals were compared as
three groups, cases of Barrett’s syndrome, gastroesopha-
geal reflux disease patients (GERD) and controls. Intake
of dietary iron was negatively associated with Barrett’s,
i.e. decreased risk with increased intake (see Summary
Table 9). This was more obvious for longer segments
of Barrett. Similar was seen for Barret cases vs. GERD
controls. These observations were supported by lower s-
Ft and serum transferrin saturation among Barrett’s
Esophagus cases than other cases. Since this is a case 
control study pointing in the opposite direction than the
hypothesis based on animal studies, the evidence must
be regarded as inconclusive (grade 4).
Miscellaneous cancers
In a case-control study of 315 case-control pairs (study
quality B) of the association between total intake of
iron (dietsupplements) by mothers during the pericon-
ception period, and the occurrence of medulloblastoma/
primitive neuroectodermal tumors of the brain during
childhood, the adjusted OR for iron was 0.5 (95% CI:
0.30.9; Ptrend0.008), and hence suggestive of a pro-
tective effect of high total iron intake (68). However,
the authors remark that a lack of internal consistency
between the findings for supplement use, intake from
foods, and intake from supplements and foods combined,
decrease their confidence in the results. The study must be
regarded as inconclusive.
The complementary search also yielded one study on
heme iron intake and the risk of bladder cancer, and one
study on the association between maternal iron supply
and the risk of infant leukemia (69, 70). None of the
studies found any association between iron intake and
cancer.
Health effects of different dietary iron intakes
Citation: Food & Nutrition Research 2013, 57: 21667 - http://dx.doi.org/10.3402/fnr.v57i0.21667 11
(page number not for citation purpose)
Rheumatoid arthritis
One paper on iron intake and risk for rheumatoid
arthritis was evaluated, quality grade B. The study by
Benito-Garcia et al. is a prospective study on a large
cohort, i.e. nurses’ health study (71). The background to
this study lies in results from former studies indicating
that high protein intake is involved in the etiology of
rheumatoid arthritis (RA) and low protein diminished
RA symptoms. The paper by Benito-Garcia et al. refer
to ecological observation showing lower incidence of
RA where meat intake is low, and the large European
prospective investigation, EPIC, associated red meat and
protein intake with risk for inflammatory polyarthritis.
Therefore Benito-Garcia et al. tested the association
between iron intake and RA in the large prospective
Nurses health study. None of these associations with RA
were found, neither for iron nor for meat or protein
intake. The authors mention several possible reasons
for the discrepancy between their results and those of
Pattison et al. (72) for red meat and protein intake, which
they did not confirm, such as different methods to collect
data, FFQ vs. 7-day food diary; different origin of dietary
protein in the US and European diets; different diagnosis
i.e. inflammatory polyarthritis (inflammation in 2 or
more joints) vs. RA verified by a screening questionnaire
and medical records (72).
The results from these studies did not support the
hypothesis that iron intake is associated with RA so there
is no conclusive evidence for this association (grade 4).
Gastrointestinal side effects in pregnancy
The objective of a study by Gill and co-workers (study
quality C) was to determine if decreasing iron exposure
in pregnancy can mitigate nausea and vomiting (73).
Data were collected from a prospective cohort, Motherisk
Program in Toronto. Women (n97) experiencing nau-
sea and vomiting were advised to discontinue prenatal
multivitamin administration (including 2760 mg of iron)
and use instead folic acid and a usual multivitamin.
The results showed that 67 or two thirds of the women
reported improvement and less nausea and vomiting.
The authors concluded that avoiding iron-containing
supplements, in the first trimester is effective in improving
nausea and vomiting in pregnancy in the majority of
women suffering from morning sickness. The authors
also mention that taking iron supplements in the first
trimester has been considered unnecessary in most cases,
which also supports avoiding extra iron intake during this
time. The study cannot be used to determine total iron
intake in pregnancy.
Milman et al. (study quality B) assessed gastrointest-
inal side effects of iron prophylaxis in pregnancy by
randomizing blindly 404 healthy women in four groups
receiving varying amounts of supplemental iron (20, 40,
60 or 80 mg Fe/day as ferrous fumarate), taken at
bedtime (74). Side effects were recorded from an inter-
view at 18, 32 and 39 weeks of gestation. The results
showed little difference in gastrointestinal effects between
the different levels of supplemental intake and com-
pliance to supplement intake was also reported to be
similar. However, constipation and black feces seemed
more frequent in those taking 80 mg/day of supplemental
iron (PB0.04 and PB0.001, respectively). The authors
concluded that 2080 mg/day of supplemental ferrous
iron fumarate taken between meals had no clinically
significant side effects and that iron prophylaxis to
pregnant women should not be compromised by undue
concern of side effects. Dietary intake was not assessed,
so this study cannot be used to determine total iron
intake in pregnancy.
The different findings and conclusions from the two
studies might be due to different types of iron containing
supplements, different time periods in pregnancy, i.e. first
trimester vs. second and third trimesters and insufficient
power. There is no conclusive evidence (grade 4) regard-
ing the association between iron prophylaxis and gastro-
intestinal side effects in pregnancy.
Maternal iron intake in pregnancy and hypospadia
in male offspring
Increase in frequency of hypospadias has put forward the
question of possible causes in the environment, e.g.
brought to the fetus in supplements or diet. North and
Golding together with the ALSPAC study team investi-
gated the possible role of maternal diet in the origin of
hypospadias in the prospective ALSPAC study (75). With
special emphasis on a vegetarian diet, mainly because
of a possible role of phytoestrogens in the etiology of
the disease, they also found an association between
hypospadias and omnivore diet supplemented with iron
(OR2.07; CI: 14.3). Both vegetarian diet and influ-
enza early in pregnancy showed stronger associations
with hypospadias, than found for iron supplement taken
by omnivores. Of the 7,928 mothers only 163 reported
to buy only organic food, but none of these had a son
with hypospadias. The authors put main weight on the
findings for vegetarian diet and for influenza, but dietary
questions were answered in week 32. Sample size cal-
culations and power were not reported. It is not possible
to judge intake of total iron from the study, and the
amount of supplemental iron is not described. Multi-
ple testing for certain factors was made, but did not
exclude by chance findings and to check for all possible
confounders.
This study may indicate some association between iron
supplement and hypospadias, without being able to give
information about the amount and type of intake and
to adjust for possible confounders. Thus, the study
gives no conclusive evidence (grade 4) regarding an
association between maternal iron intake in pregnancy
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and hypospadia in the male offspring. Further studies
are needed in the area.
Interactions between iron and other food
components
Even though not covered by our initial research ques-
tions, our search generated several papers regarding inter-
actions between iron and other food components, and we
summarize the findings briefly here.
Zinc and copper
Since copper and zinc are also divalent metals, it has
been suggested that a high iron intake may competitively
inhibit intestinal absorption of these two minerals, po-
tentially leading to deficiencies. Copper is believed to
use the same transporter protein as iron, divalent metal
transporter 1, while zinc is believed to use specific zinc
transporter proteins (76).
We included three intervention studies, all of quality A,
investigating the effects of iron supplements on zinc
and copper absorption or on zinc status. In the study
by Domello¨f et al. 25 breast-fed infants received iron
supplements (1 mg/kg/day, corresponding to about 7.5
mg/day) or placebo for 25 months. Zinc and copper
absorption were evaluated using stable isotope methods.
No effect of iron supplements on zinc or copper
absorption was found in this study (77). Harvey et al.
randomized 13 pregnant women to receive iron supple-
ments equaling 100 mg daily or placebo and found no
significant difference in plasma zinc concentrations,
exchangeable zinc pool (a measure of zinc status), urinary
zinc secretion or fractional zinc absorption (78). Troost
et al. investigated the effects of a single dose of 100 or
400 mg iron versus placebo in 55-year-old ileostomy
subjects and found lower zinc absorption but no differ-
ence in copper absorption after iron administration (79).
The three studies are performed in very different
categories of subjects and provide conflicting evidence
with regard to the effect of iron supplementation on zinc
and copper absorption. When excluding the study
that was performed in a population less relevant to the
NNR (ileostomy subjects), there is no conclusive evi-
dence (grade 4) that iron supplements affect zinc or
copper absorption.
Tea
Two papers, both evidence quality C, have reviewed
the association between tea consumption and iron status
(80, 81). The two reviews have a number of overlapping
references.
The first review summarizes a total of 16 studies
(N8,613) of which six are on infants and children
(N2,942), six are on premenopausal women (N
2,874), two are on men (N1,402) and two are on the
elderly (N1,395) (80). Unfortunately, the review does
not give any quantitative data (e.g. RR or OR) on the
impact of tea consumption on iron status. Generally,
the results showed that in groups with high prevalence of
ID (infant/child, women) tea consumption was inversely
associated with s-Ft and/or Hb. This association dis-
appeared when adjusting for confounding dietary factors.
The authors conclude that tea consumption does not
influence iron status in populations having adequate iron
stores. Only in individuals with marginal iron stores there
may be a negative association between tea consumption
and iron status.
The second review identified 36 references specific
to the effects of black tea on iron absorption or iron
nutrition (81). This study has a possible, non-declared
conflict of interest since it is supported by PG Tips Tea,
part of Unilever Bestfoods UK, and one of the authors is
a consultant at Unilever Bestfoods UK. The authors
found evidence that consumption of black tea inhibits
iron absorption from test meals, although to a variable
extent and probably less so in complete diets. When it
comes to the influence of tea drinking on iron status there
are indications that tea consumption in populations at
risk of ID is negatively associated with iron status
markers, or there are more cases of ID and IDA among
tea drinkers compared to non-tea drinkers. However, the
authors state that many of the studies report additional
associations between iron status markers and other fac-
tors, both dietary and non-dietary, underlining the com-
plexity of interactions determining iron absorption and
iron status.
The authors conclude that there is no need to advise
any restrictions on tea drinking in healthy people with no
risk of ID. In groups at risk of ID, the advice should be to
drink tea between meals (at least 1 h after eating).
Taken together, the evidence summarized in these two,
semi-systematic reviews indicate (grade 3) that tea drink-
ing would have a minor impact on iron nutrition in the
Nordic countries, since tea drinking is not so widespread,
and since most people have adequate iron stores. Only
in sub-populations at increased risk of ID, should tea
drinking between meals only be considered as advice.
Mortality
During the review process of this manuscript, an addi-
tional publication from 2011 was discovered, which was
not included in our original search: A cohort study of
38,772 older women in the Iowa Women’s Health Study
who from a mean age of 62 years were followed for 22
years and the effects of self-reported dietary supplements
on mortality were investigated (82). The use of multi-
vitamins, vitamin B6, folic acid, iron, magnesium, zinc,
and copper were associated with increased risk of total
mortality, however only the effects of multivitamins and
copper remained significant when correcting for multiple
comparisons.
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Discussion
Anemia and iron status
Effects of iron intake in infants and children
Globally, it is estimated that about 25% of pre-school
children have IDA (83). The prevalence of IDA in
European infants is very low below the age of 6 months
but increases to 23% at 12 months (84) and 37% at
13 years of age (8587). In the 1990s, non-anemic ID
(defined as s-FtB12 mg/L) had a prevalence of 2640%
among 12-month-olds in the Nordic countries (88, 89)
but more recent data shows a lower prevalence around
6% (90). The health consequences of non-anemic ID are
less well known and the prevalence is highly dependent
on the definition of ID, which is controversial during
infancy (91).
Since the Hb concentration falls rapidly after birth,
and iron is transferred from Hb to iron stores, the
term, normal birth weight, healthy, breast-fed newborn
is assumed to be virtually self-sufficient with regard to
iron during the first 46 months of life, even though
breast milk has a very low iron concentration (0.3 mg/L).
Iron supplements are therefore usually not recommended
for healthy, breast-fed infants. The four studies included
in this review do not provide sufficient evidence that
term, normal birth weight, healthy, breast-fed infants
need additional dietary iron before 6 months of life in
populations with a low general prevalence of IDA such
as the Nordic countries.
Formula-fed infants theoretically have higher iron
requirements due to the lower bioavailability of iron
from formula compared to breast milk. Considering only
the difference in bioavailability, an iron concentration of
about 1.5 mg/L in infant formula would be sufficient but,
traditionally, much higher levels of fortification have been
used. In Europe, infant formulas are usually iron fortified
to a level of 48 mg/L while American guidelines suggest
1012 mg/L (92). The small intervention study included in
this review, comparing 2 vs. 4 mg Fe/L during the first 6
months of life, does not give conclusive evidence on which
iron concentration is needed in infant formula to prevent
ID. Global guidelines coordinated by the European
Society for Pediatric Gastroenterology, Hepatology and
Nutrition (93) recommend fortification of infant formula
with 0.31.3 mg Fe/100 kcal, corresponding to 28.5 mg
Fe/L. We conclude that concentrations of 48 mg Fe/L in
formulas for infants B6 months of age seems to be safe
and effective based on current practice in Europe.
It is known that a low intake of iron-rich complementary
foods increases the risk of ID in infants (94). Unfortu-
nately, the studies included in this review do not give
any evidence on iron requirements in infants and young
children above the age of 6 months. However, one study
suggested that a high intake of cow’s milk (300500 mL/
day) may be associated with ID. Therefore, it seems
prudent to avoid such high intakes of cow’s milk in in-
fants and toddlers. This is supported by the reduced
prevalence of ID at 12 months in Icelandic infants after
new recommendations suggesting the avoidance of cow’s
milk before 12 months of age and the use of iron-fortified
follow-on formula (90).
Effects of iron supplementation in fertile women
Daily iron requirement is high among women during
childbearing years, because of blood loss during men-
struation. This loss is variable between women, but the
variation is less among adolescent girls than among adult
women (95).
The daily iron intake required to meet the need of
90 and 95% of adult women is estimated to be 14.8
and 18.5 mg/day, respectively, assuming 15% absorption
(see NNR4 Table 34.2). Recommended daily iron intake
is 15 mg/day for women of childbearing age.
It should be emphasised that these calculations assume
that blood losses in menstruation are the same as in the
1960s, although it is known that nowadays blood loss is
substantially less due to the use of oral contraceptives.
In a more recent study, median menstrual blood loss was
17.6 mL/day in 90 UK women of childbearing age, and
median menstrual iron loss was 0.26 mg/day, with 70% of
the women losing less than 0.5 mg/day (96). Approxi-
mately 30% of the women used oral contraceptives.
We found no studies examining the effect of dietary
iron intake in iron-replete women of childbearing age.
However, two small studies were found looking at iron
status markers in women with low iron stores. In one
study, an intake of between 11.5 and 13.9 mg Fe/day
over 8 weeks maintained iron status independently of
whether an oily fish or a red meat diet was supplied.
In another study, 16 weeks intake of 500 mL/day of
fruit juice supplemented with micro-encapsulated iron-
pyrophosphate (total iron intake approx. 30 mg/day)
increased s-Ft levels from approximately 25 to approxi-
mately 40 ng/mL, whereas fruit juice only (total iron
intake approximately 15 mg/day) resulted in no increase
or decrease in s-Ft levels.
Taken together, these two studies indicate that approxi-
mately 15 mg Fe/day is sufficient to maintain iron status
in women with low iron stores. Supplementation with
an additional 15 mg Fe/day appears sufficient to sub-
stantially improve iron status over 16 weeks. This is in
accordance with NNR4, which states that 14.8 mg Fe/day
covers the iron need of 90% of women in fertile age.
Iron supplementation in pregnancy
Maternal iron need during pregnancy increases slowly as
the pregnancy progresses, because of growth and main-
tenance of the foetus and the uterus, increase in red blood
cell count and expected iron losses when giving birth.
Current Norwegian recommendations about the intake of
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iron supplements during pregnancy are based on mea-
surements of s-Ft concentrations (97). Recommendations
regarding dietary iron intake in pregnant women are
based on the NNR 2004 recommendation for non-
pregnant women. However, the physiological need of
some women for iron cannot be satisfied during the last
two thirds of pregnancy with foods only and supple-
mental iron is needed. NNR 2004, in accordance with the
recommendations of SCF (98), do not give recommenda-
tions for dietary iron during pregnancy. The US recom-
mendation for pregnancy is 27 mg/day (33).
The studies by Milman et al. (28), Makrides et al. (26),
and Sandstad et al. (27) provide probable evidence (grade
2) that supplementing with 40 mg Fe/day from week
1820 of gestation without any knowledge of s-Ft status
in early pregnancy, will achieve prevention of ID in more
than 90% and IDA in more than 95% of women at
delivery and at 68 weeks postpartum. If we screen for
s-Ft levels in early pregnancy (week 1518), then 60 mg
or 40 mg Fe/day will prevent ID in more than 90% and
IDA in 100% at delivery in women having FtB30 mg/L
or Ft between 30 and 70 mg/L, respectively, in early
pregnancy. Women having Ft70 mg/L would normally
not require iron supplementation.
There is no convincing evidence that postpartum
supplementation with 80 mg Fe/day gives any lasting
benefits with regard to maternal anemia.
Effects on offspring of iron supplementation of pregnant
women
There is no convincing evidence that iron supplementa-
tion of pregnant women in a Scandinavian setting would
improve iron status or cognitive development in off-
spring. Indeed, several high quality RCTs show a lack of
such effects. A more effective method for improving
the iron endowment of newborns is to practice delayed
clamping of the umbilical cord at birth, which recently
was shown to reduce the risk of ID at 4 months of age
in Swedish infants (99).
Physical performance
From the two studies considered, we conclude that iron
supplementation does not increase physical performance
in iron-normal individuals, but may have a positive effect
on the performance of individuals with IDA.
Cognitive, motoric, and behavioral function
Effects on the offspring of iron given to the pregnant mother
There is no evidence that iron supplementation during
pregnancy improves cognitive or behavioral outcomes in
the offspring in a Nordic setting.
Effects of iron given to infants and children
During early childhood, growth and development of the
central nervous system is rapid and iron is critical for this
process. Animal studies have shown that iron is essential
for several aspects of brain development: Myelination,
monoamine neurotransmitter function, neuronal and
glial energy metabolism, and hippocampal dendritogen-
esis (100). Several case-control studies in children have
shown a consistent association between IDA in early
childhood and long-lasting poor cognitive and behavioral
performance and an association between early ID and
later developmental scores has been observed also in the
Nordic setting (3, 101).
The study by Friel et al. (14) and the meta-analysis by
Szajewska et al. (41) give limited suggestive evidence
(grade 3) that preventive iron supplementation of infants
may improve psychomotor development. This is sup-
ported by a previous meta-analysis by Sachdev et al. from
2005 of 17 randomised clinical trials in children (015
years) that included cognitive and psychomotor out-
comes, which showed that iron supplementation or the
intake of iron fortified foods had a significantly positive
effect on mental development indices, equivalent to 1.52
points of 100 (102). This meta-analysis included pre-
ventive trials in risk groups, mostly in low-income
countries, and therapeutic trials in children with diag-
nosed IDA and was thus not included in this systematic
review.
However, there is insufficient evidence to conclude that
preventive iron supplementation given before 6 months
of life has beneficial effects on cognition or psychomotor
development in healthy, breast-fed infants of normal
birth weight in low-risk populations such as the Nordic
countries.
Even though iron supplements are not recommended
for healthy, normal birth weight infants before 6 months
of age in the Nordic countries, there is one risk group
that needs to be considered: Low birth weight infants.
Low birth weight, defined as a birth weight B2,500 g,
affects 4% of newborns in the Nordic countries and is a
major risk factor for ID in children.
A meta-analysis from 1992, based on older studies,
showed that prophylactic iron at a dose of 2 mg/kg/day
given to LBW infants, most with birth weights 1,500
2,500 g, leads to a significantly reduced incidence of
anemia at 6 months (103).
In a study by Friel et al. 58 infants with an average
birth weight of 1,500 g were randomized to different
infant formulas resulting in iron intakes of 36 vs. 23
mg/kg/day up to 9 months of age (104). There was no
difference in anemia or neurodevelopment at 12 months.
However, the high-iron group had higher glutathione
peroxidase concentrations (a marker of oxidative stress),
lower plasma zinc and copper levels and a higher number
of respiratory tract infections, suggesting possible adverse
effects with the higher iron intakes.
In a recent study, Berglund et al. randomized 285
marginally low birth weight infants (2,0002,500 g) to
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receive 0, 1 or 2 mg/kg/day of iron from 6 weeks to 6
months of age and found that iron supplementation
effectively prevented IDA (9.9, 2.7 and 0% respectively,
P0.004) and ID (36, 8 and 4%, PB0.001) at 6 months
(105). In a follow-up of this study, it was observed that
those marginally low birth weight children who were
iron supplemented during early infancy had significantly
lower prevalence of behavioral problems at 3 years of age
(2.8 vs. 12.7%, P0.027) [Berglund et al. submitted].
This supports the WHO recommendation (106) that iron
supplements should be provided to all low birth weight
infants, including those of marginally low birth weight,
which includes moderately pre-term and term, small for
gestational age infants. The Berglund study suggests that
a dose of 12 mg/kg/day from 6 weeks to 6 months of age
is a safe and effective dose in the Nordic population.
Possible adverse effects
One recent study (107) (retrieved in complementary
search, not included in evidence tables) investigated the
long term effects of an intervention in which healthy,
non-anemic, Chilean infants (N835) with birth weights
3 kg, were randomized to receive a high iron (12 mg/L)
or low iron (2.3 mg/L) infant formula from 612 months
of age. The initial results from this study showed no
significant effect on IDA at 12 months (about 3% in both
groups) (108). In a follow-up at 10 years of age (N494),
several dimensions of cognitive and motor development
were tested and the children in the high-iron group had
lower scores for all outcomes, significantly so for visual
motor integration (107). This negative effect seemed to
be limited to those infants who were initially iron-replete
(Hb120 g/L). This study suggests possible adverse
effects of excessive iron intake during late infancy but
has several weaknesses, including a high attrition rate
(41%) and needs to be confirmed by other studies before
any conclusion can be drawn.
Effect of iron given to school children or adults
Falkingham et al. has performed a meta-analysis (study
quality A) of RCTs of the effects of iron on cognitive
functions when given to children aged 618 years, or to
adult, pre-menopausal women (109). This meta-analysis
by Falkingham was not included in the systematic review
since it was mainly based on studies in populations
not relevant for the NNR. However, the results were still
interesting from a mechanistic point of view: a positive
effect was found on attention/concentration (three
studies) in anemic women or Indian school children at
high-risk of ID. In contrast, no significant effects were
observed with regard to intelligence, memory, psycho-
motor function or scholastic aptitude. This meta-analysis
provides probable (grade 2) evidence that iron supple-
ments improve attention and concentration in school
children or adults who are anemic or who belong to a
high-risk group for IDA. However, it is not clear that
this is relevant to populations with a low risk of IDA,
e.g. Nordic countries.
Fetal and child growth
Fetal growth and pregnancy duration
We found no evidence that, in a Nordic setting, iron
supplements during pregnancy improves fetal growth
or reduces the proportion of children born prematurely,
small for gestational age or with low birth weight.
Child growth
It has been suggested that iron may have adverse effects
in iron-replete children. However, this review shows
that there is not enough evidence to conclude that iron
supplements impair growth in iron-replete children, even
though more studies are needed.
Hypertension and cardiovascular disease
Hypertension
There is no convincing evidence for an association
between high iron intake in pregnancy and lower blood
pressure in the offspring (47, 48). Two studies, one
prospective and one cross sectional, showed a protective
effect of non-heme dietary iron consumption against
higher blood pressure levels in adults (49, 50). However,
the evidence is insufficient to draw a conclusion.
Cardiovascular disease
A relation between heme iron intake and cardiovascular
disease is evaluated as suggestive based on the SACN
report (UK’s Scientific advisory committee on nutrition
treated iron and cardiovascular disease in their report
on iron and health from 2010). This has also been shown in
the Iowa women’s health study cohort, for women having
10 g of alcohol per day and more clearly at 30 g/day (51).
Diabetes mellitus
We found three large studies examining the association
between iron intake and T2D in a total of 35,698 men
(53) and 120,729 women (13, 52). The studies reported
similar figures for the lowest and the highest quintile of
heme iron intake, and they arrived at the exact same
relative risk for T2D (RR1.28). No effect or an inverse
effect on the risk of T2D was seen for non-heme iron or
for total iron intake. Thus, these studies indicate that
there is an association between heme iron intake and the
risk of developing T2D. Indirectly, the two case studies
looking mainly at the association between markers of
iron stores and risk of T2D (54, 55) supports the results
above, since they found that cases with T2D also had the
highest intake of heme iron.
The studies above adjusted their data for many known
confounders. However, the fact that heme iron intake is
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closely determined by the intake of red meat, that subjects
with high heme iron intake had significantly less healthy
behavior (diet, physical activity, smoking, BMI) (13) and
the absence of an effect of total iron intake, makes it likely
that there are other dietary factors (e.g. nitrites, sodium,
glycation products, inflammatory mediators) or lifestyle
factors rather than iron that increase the risk of T2D.
With regard to gestational diabetes, Qiu et al. found
in a study of 3,158 pregnant women that a high intake
of heme iron during pregnancy increased the risk of
developing GDM (56). Bowers et al. reached the same
conclusion when studying the association between pre-
pregnancy heme iron intake and the risk of GDM in
13,475 women (57). Thus, a high intake of heme iron
both before and during pregnancy appears to signifi-
cantly increase the risk of GDM.
Taking all of these studies together, we conclude that
there is probable evidence (grade 2) for the association
of heme iron intake with the risk of T2D and GDM
even though these associations are not necessary causal.
Since there is no evidence that total iron intake is asso-
ciated with an increased risk of T2D, this does not have
any implication for iron RDIs.
A recent meta-analysis, including data from 204,159
individuals, confirmed the association between red meat
intake, particularly processed red meat, and increased risk
of T2D (110). Possible health effects of meat, unrelated to
iron, and recommendations regarding the intake of red or
processed meat intake are beyond the scope of this paper.
The study investigating the association between iron
intake and the development of T1D in infants aged 14
months, found an association of T1D with high total iron
intake (58). The authors suggested that this was due to
higher intake of iron-fortified formula, although formula
intake was not recorded. An alternative explanation could
be the higher intake of cow’s milk proteins through
formula, which seems to be associated with T1D (111).
Thus, there is no conclusive evidence (grade 4) for the
association of iron intake and the development of T1D.
Cancer
According to a recent meta-analysis, individuals carrying
the C282Y hemochromatosis mutation have an increased
risk of hepatocellular carcinoma (112). Regarding extra-
hepatic malignancies in the general population, there were
some studies cited in NNR4 indicating an increased risk of
colon cancer and also other cancers related to high iron
stores. However, a causal relationship between iron and
extra-hepatic cancer could not be established. We found a
total of 12 studies examining the possible relationship
between dietary iron intake and various forms of cancer.
No convincing evidence that dietary iron intake is
associated with increased risk of colon cancer, lung
cancer, breast cancer, esophageal cancer or other cancers,
could be found.
Rheumatoid arthritis
There is insufficient evidence to support iron intake
being associated with RA, but such an association cannot
be excluded. However, based on the paper by Benito-
Garcia et al. (71), an exploration of prospective data
having information on dietary intake, including red meat,
protein and iron, and the development of RA would be
valuable.
Gastrointestinal side effects
Two studies on gastrointestinal side effects and iron intake
in pregnancy found different results and no conclusions
can be drawn about the association.
Hypospadias
One study indicated some association between iron
supplement and hypospadias. However, it is not possible
to give information about the amount and type of intake or
to adjust for possible confounders. No conclusion could be
suggested. Further studies are needed in the area.
Interaction between iron and other food
components
Copper and zinc
We included three intervention studies, all of quality A,
investigating the effects of iron supplements on zinc and
copper absorption or on zinc status. The three studies
provide no conclusive evidence (grade 4) with regard to
the effect of iron supplementation on zinc and copper
absorption.
Tea
Tea consumption does not influence iron status in
populations having adequate iron stores. We conclude
that tea drinking has only a marginal impact on iron status
in the Nordic countries, since tea drinking is not very
widespread, and since most people have adequate iron
stores. Only in sub-populations at increased risk of ID tea
drinking only between meals may be considered as advice.
The impact of ethnic multiplicity
Ethnic multiplicity has become widespread in the Nordic
countries and many ethnic minority groups may have dif-
ferent nutrition profiles compared to the general popula-
tion and some hereditary disorders, e.g. thalassemia are
more common. It is difficult to cover these differences in
recommendations for the population at large. Our search
retrieved one study where this issue was addressed to
some extent. In the SACN report from UK (46),
they found that iron intakes of UK ethnic minority
groups above 16 years of age were similar to the general
population. The prevalence of anemia was low in men (0
4%) compared to women, ranging from 67% in Irish and
Chinese to 29% in Indian women. Furthermore, the
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prevalence of ID and IDA in infants and children was
unclear due to limited data on biochemical markers of iron
status. Data for the Nordic countries are, to a large extent,
lacking even though one study has showed a higher
prevalence (20.0%) of anemia among pregnant immigrant
women (of eastern Mediterranean, African, or Asian
origin) compared to ethnic Danish women (4.9%) (113).
We conclude that further research on this issue is needed,
and we suggest that it should be addressed in the next
NNR.
Conclusions
The studies included in this systematic review provide
additional evidence for the importance of dietary iron
intake for different health outcomes. Most studies
have focused on risk groups for ID: young children
and fertile women. There is some evidence that preven-
tion or treatment of ID and IDA improves cognitive/
motor/behavioral development in young children and
that treatment of IDA improves attention and concentra-
tion in school children and adult women.
With regard to newborns and infants up to 6 months
of age, we conclude that:
(1) There is insufficient evidence that healthy normal
birth weight, exclusively breast-fed infants need
additional dietary iron before 6 months of life in
the Nordic countries.
(2) An iron concentration of 48 mg/L in infant
formulas seems to be safe and effective for normal
birth weight infants.
(3) Infants with low birth weight (B2,500 g) should
receive iron supplements (12 mg/kg/day) during the
first 6 months of age in order to prevent IDA and
this may also reduce the risk of behavioral problems
later on.
(4) Late umbilical cord clamping should be practiced
since this reduces the risk of ID in infants.
With regard to infants above 6 months of age and
toddlers, we conclude that:
(1) Iron-rich complementary foods (mainly meat pro-
ducts and iron-fortified foods) should be provided in
order to achieve recommended iron intakes.
(2) High intakes of non-iron-fortified cow’s milk
(300500 mL/day) should be avoided.
With regard to pregnant women, we conclude that
iron supplementation from week 1820 of gestation or
earlier should be recommended. The supplementation
could either be given as a general prophylaxis of 40 mg
Fe/day to all, or as an individual prophylaxis of 60 or
40 mg Fe/day depending on the woman’s s-Ft measured
in early pregnancy (before 15 weeks of gestation).
Both regimes would prevent ID and IDA at delivery
and at 68 weeks postpartum 90 and 95% of cases,
respectively (see Results). There is, however, no evidence
that maternal iron supplementation has any effect on the
offspring in the Nordic countries.
Overall, we did not find sufficient evidence to support
a change of the iron intakes recommended in the NNR 4.
However, one could consider adding recommendations
for infants up to 6 months of age, low birth weight infants
and pregnant women.
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Appendix 1. Search terms [initial search sept 2010]
(‘‘Iron, Dietary’’ [Mesh] OR
(‘‘Iron’’ [Mesh] AND ‘‘Dietary Supplements’’ [Mesh]))
AND (‘‘Neurobehavioral Manifestations’’ [Mesh] OR
‘‘Anemia’’ [Mesh] OR
‘‘Mental Processes’’ [Mesh] OR
‘‘Behavior’’ [Mesh] OR
‘‘Human Development’’ [Mesh] OR
‘‘Growth’’ [Mesh] OR
‘‘Iron Overload’’ [Mesh] OR
‘‘Arthritis’’ [Mesh] OR
‘‘Neoplasms’’ [Mesh] OR
‘‘Cardiovascular Diseases’’ [Mesh] OR
Neurobehavioral Manifestations [Title/abstract] OR
Anemia [Title/abstract] OR
Mental Processes [Title/abstract] OR
Behavior [Title/abstract] OR
Human Development [Title/abstract] OR
Iron Overload [Title/abstract] OR
Arthritis [Title/abstract] OR
Cancer [Title/abstract] OR
Cardiovascular Diseases [Title/abstract] OR
‘‘adverse effects’’ [Subheading])
AND (‘‘humans’’ [MeSH Terms]
AND ‘‘2000/01/01’’ [PDAT] : ‘‘2010/08/24’’ [PDAT])
Appendix 2. Exclusion history
Event No. of articles
Exclusion
criteria
No. of articles
excluded
No. of articles
remaining
Search with final version of search criteria 1070 (abstracts) Level 1 106 964
Second list of abstracts 964 (abstracts) Level 2 694 270
Full-text articles received 2701* Level 3 221 491
Full-text articles for evidence table generation 491 Level 4 5 441
Full-text articles added from other sources 6 Level 14 2 481
Complementary search performed 187 (abstracts) Level 12 79 108
Second round of complementary search abstracts 108 Level 3 61 47
Full-text articles ordered from complementary search 47 Level 34 47$
Diabetes search performed 132 (abstracts) Level 12 124 8
Full-text articles ordered from diabetes search 8 Level 34 2 6
*This is the SACN report.
$Ar1cles were not sub2ect to 3AT evalua1on
Exclusion criteria:
1. Level 1: Study population not relevant to NNR.
2. Level 2: As Level 1language, animal or cell studies, letters, news, congress reports.
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